Massimo Aglietta
Overview
Explore the profile of Massimo Aglietta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
244
Citations
6478
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Massa A, Vita F, Peraldo-Neia C, Varamo C, Basirico M, Raggi C, et al.
Cancers (Basel)
. 2025 Jan;
17(1.
PMID: 39796759
Background/objectives: Intrahepatic cholangiocarcinoma (iCCA) is a malignant liver tumor with a rising global incidence and poor prognosis, largely due to late-stage diagnosis and limited effective treatment options. Standard chemotherapy regimens,...
2.
Overman M, Gelsomino F, Aglietta M, Wong M, Limon Miron M, Leonard G, et al.
J Immunother Cancer
. 2024 May;
12(5).
PMID: 38821718
Background: Programmed death-1 (PD-1) inhibitors, including nivolumab, have demonstrated long-term survival benefit in previously treated patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (CRC). PD-1 and lymphocyte-activation gene 3...
3.
Moro G, Ragusa P, Previti C, Comandone A, Airoldi M, Aglietta M, et al.
J Surg Oncol
. 2024 Feb;
129(6):1165-1170.
PMID: 38419194
Background And Methods: This retrospective observational study analyzes how the COVID-19 pandemic affected surgical oncology healthcare in a large sample from Piedmont, Northern Italy. Patients admitted for regular hospitalization were...
4.
Giraudo L, Cattaneo G, Gammaitoni L, Iaia I, Donini C, Massa A, et al.
J Exp Clin Cancer Res
. 2023 Nov;
42(1):310.
PMID: 37993874
Background: Even acknowledging the game-changing results achieved in the treatment of metastatic melanoma with the use of immune checkpoint inhibitors (ICI), a large proportion of patients (40-60%) still fail to...
5.
Aglietta M, Chiarion-Sileni V, Fava P, Guidoboni M, Depenni R, Minisini A, et al.
Tumori
. 2023 Jul;
109(6):537-545.
PMID: 37417313
Background: Brain metastases (BM) and lactate dehydrogenase (LDH) levels above the upper limit of normal (ULN) are associated with poor prognosis in patients with melanoma. Although treatment with the BRAF...
6.
Casadei-Gardini A, Leone F, Brandi G, Scartozzi M, Silvestris N, Santini D, et al.
Front Oncol
. 2023 Apr;
13:1128930.
PMID: 37091141
Cholangiocarcinoma is a rare group of tumors that involve the hepatic biliary tree. Prognosis for patients with cholangiocarcinoma remains dismal. Herein, we present survival trends over a long time period...
7.
Marinangeli F, Tonini G, Aglietta M, Gentili M, Cappellini F, Giacomelli L, et al.
Future Oncol
. 2023 Apr;
19(24):1669-1676.
PMID: 37042452
Treatment of cancer pain remains suboptimal worldwide. In Italy, a law requires that pain be regularly assessed and reported in both medical and nursing records. To provide a homogeneous form...
8.
Fibroblasts Impair Migration and Antitumor Activity of NK-92 Lymphocytes in a Melanoma-on-Chip Model
Iaia I, Brancato V, Caballero D, Reis R, Aglietta M, Sangiolo D, et al.
Bioengineering (Basel)
. 2023 Jan;
10(1).
PMID: 36671624
Adoptive cell therapy in solid tumors, such as melanoma, is impaired, but little is known about the role that the fibroblasts present in the tumor microenvironment could exert. However, the...
9.
Lombardi P, Aimar G, Peraldo-Neia C, Bonzano A, Depetris I, Fenocchio E, et al.
Oncol Rep
. 2022 Dec;
49(2).
PMID: 36562382
Fluoropyrimidines (FP) are the backbone chemotherapy in colorectal cancer (CRC) treatment; however, their use is associated with cardiotoxicity, which is underreported. In the present study, it was aimed to prospectively...
10.
Rotolo R, Leuci V, Donini C, Galvagno F, Massa A, De Santis M, et al.
Clin Cancer Res
. 2022 Sep;
29(3):621-634.
PMID: 36165915
Purpose: Antibodies against the lymphocyte PD-1 (aPD-1) receptor are cornerstone agents for advanced non-small cell lung cancer (NSCLC), based on their ability to restore the exhausted antitumor immune response. Our...